GALDERMA
EST. 1981

August 9, 2021

Subject: EudraCT 2013-001796-20 Results posting

RD.03.SPR.40214E

STUDY TITLE
Efficacy, safety and pharmacokinetics of 2 concentrations and 2 dosage regimens of CD5789 in subjects with Lamellar Ichthyosis

EudraCT Guidelines state Sponsor must post a pdf document in the results section for trials that were approved but never started and state the reason for the premature interruption. This document must be filed to close the query in EudraCT.

Nathalie Wagner, Sr. Clinical Pharmacokinetics Manager and Dr. Michael Graeber, Chief Medical Advisor confirmed sites for this study were selected and an Investigator Meeting was held in Nice, France. The study was then terminated based on internal strategic decisions therefore no sites were ever opened. Galderma sold the rights to the LL indication to Mayne Pharma.

Regards,

DocuSigned by:
Christophe Piketty
45EE98EC941B444...
August 9, 2021

Christophe Piketty, MD, PhD
Global Senior Program Lead
Galderma Research & Development